Clinical trials: Locally Advanced Esophageal Cancer
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Esophageal Cancer, Gastric Cancer
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of…
- Trial name
- NCT00004233
- Testing
- fluorouracil, leucovorin calcium, triacetyluridine
- Where
- 97 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
This is a randomized, prospective, multicenter study.
- Conditions
- Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy, Chemoradiotherapy
- Trial name
- NCT02399306
- Testing
- Enteral nutrition, radiotherapy
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Cancer
Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW
Radiation and chemotherapy can shrink the tumor. For certain types of cancer, immunotherapy is added to further reduce the tumor size.
- Trial name
- GLOW (NCT07196384)
- Testing
- Spectroscopy system, Nivolumab-800CW, Durvalumab-680LT
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
The aim is to assess the relative efficacy of S-1 de-escalation therapy vs. continuation of chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in terms of overall survival.
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- MATEO (NCT02128243)
- Testing
- S-1 de-escalation, Chemotherapy by Investigator's choice
- Where
- Germany
- Volunteers
- 242 people
- Sponsor
- AIO-Studien-gGmbH
Esophageal Squamous Cell Carcinoma
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer…
- Trial name
- NCT04644250
- Testing
- Toripalimab, Paclitaxel liposome/Carboplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Wei Ren
Esophageal Carcinoma
Induction Chemotherapy for Locally Advanced Esophageal Cancer
Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced…
- Trial name
- NCT03110926
- Testing
- mFOLFOX6, Chemoradiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Rochester
Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced…
- Trial name
- NCT07039162
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Ming-Yu Lien
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Esophageal Squamous Cell Carcinoma
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03790553
- Testing
- Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 646 people
- Sponsor
- Fudan University
Esophageal Cancer
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between tirilizumab combined with concurrent chemoradiation…
- Trial name
- TCRTOE (NCT06061146)
- Testing
- Arm A, Arm B
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Adenocarcinoma of the Gastroesophageal Junction
Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction
The high cancer related mortality has remained a significant issue of health care in Poland, Europe and worldwide. The decreasing incidence rate for carcinoma of the distal stomach and a marked trend of increasing incidence for…
- Trial name
- NCT01523015
- Testing
- preoperative chemo- and chemoradiotherapy, Surgical resection
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Lublin
Esophageal Squamous Cell Carcinoma
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial.
- Trial name
- NCT03278626
- Testing
- Nivolimumab+Carboplatin/paclitaxel+Radiation
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- NYU Langone Health
Esophageal Cancer, Adenocarcinoma
A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer
The primary objective of this study is to assess the efficacy of nimotuzumab in combination with chemotherapy and radiotherapy for the treatment of locally advanced esophageal cancer, comparing it to that of the conventional…
- Trial name
- NICE (NCT01249352)
- Testing
- Nimotuzumab, Cisplatin, Fluorouracil
- Where
- 19 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- Eurofarma Laboratorios S.A.
Esophageal Cancer
Cryotherapy for Locally Advanced Esophageal Cancer
Background: In published studies, complete response (CR) to chemoradiation occurs in only 25-30% of patients with locally advanced esophageal cancer.
- Trial name
- NCT04248582
- Testing
- Cryotherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.
Esophageal Cancer, Immunotherapy
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Although unprecedented advances have been made in the field of esophageal cancer in recent decades, the prognosis for patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains extremely poor, accounting for…
- Conditions
- Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
- Trial name
- NCT06421376
- Testing
- Cardonilizumab, Chemoradiotherapy ±immunotherapy, Radical surgery
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery
This phase III trial studies nutritional supplementation with Impact Advanced Recovery to see how well it works compared with standard nutritional supplementation in reducing complications in patients with esophageal cancer that…
- Conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8
- Trial name
- NCT04029857
- Testing
- Nutritional Supplement Drink, Nutritional Supplementation
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with…
- Trial name
- MRD2START (NCT06914011)
- Testing
- Tislelizumab
- Volunteers
- 172 people
- Sponsor
- Asan Medical Center